Agilent Technologies is a seed to Series C stage investment firm based in Santa Clara, California, United States. It has made 9 investments, with focus areas including Biotech & Life Sciences. 100% of their portfolio is in Biotech & Life Sciences. Their most common stage is series-b (56% of deals). Average disclosed round size is $35.5M (across 9 rounds with reported amounts).
Portfolio
9
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
9 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 RareCyte | Series B | $20M | Jun 2024 |
 Biofidelity | Series A | $24M | Apr 2024 |
 Molecular Assemblies Inc. | Series B | $25.8M | Mar 2022 |
 Akadeum Life Sciences, Inc. | Series B | $17.5M | Oct 2021 |
| RareCyte | Series B | $24M | Sep 2021 |
 MOBILion Systems Inc. | Series C | $60M | Jul 2021 |
 DNA Script | Series B | $75.5M | Aug 2020 |
| Molecular Assemblies Inc. | Seed | $2.3M | Dec 2016 |
 Mission Bio | Series C | $70M | — |
Top Co-Investors
F-Prime Capital2 shared
HealthQuest Capital2 shared
Casdin Capital2 shared
Beringea1 shared
University of Michigan1 shared
LifeSpan Vision Ventures1 shared
Bluestone Equity Partners1 shared
Michigan Capital Network1 shared
iSelect Fund1 shared
LYFE Capital1 shared
Argonautic Ventures1 shared
Logos Capital1 shared
Mayfield Fund1 shared
Novo Holdings1 shared
Cota Capital1 shared
Eleven Two Capital1 shared
Keshif Ventures1 shared
Alexandria Venture Investments1 shared
Octopus Ventures1 shared
BlueYard Capital1 shared
Last updated: 8 March 2026